#DMARD
Thank you. It does suck! I'm on methotrexate, failed another dmard, so waiting to hear what I can take next.
November 10, 2026 at 8:59 PM
New!

Dual-targeted therapy (two biologics or a biologic plus a targeted synthetic DMARD): conditionally recommended in selected patients with persistent active disease despite monotherapy

Consider if: IBD or PsO

#ACR26
November 9, 2026 at 3:31 PM
👉️ NSAIDs remain strongly recommended for active axSpA.

👉️Patients with poor prognostic features, including syndesmophytes or elevated CRP, may warrant initial treatment with a biologic or targeted synthetic DMARD rather than starting with NSAIDs.

#ACR26
November 9, 2026 at 3:30 PM
Managing obesity in #RheumatoidArthritis requires optimized #DMARD regimens before initiating GLP-1 receptor agonist combination therapy, according to a presentation by UCLA Health's Dr. Veena Ranganath at #ACR26.

https://www.rheumatologyadvisor.com/reports/glp-1-inflammatory-arthritis-obesity/
Addressing Obesity in Inflammatory Arthritis: The Role of GLP-1 RAs
Obesity blunts therapeutic response in rheumatoid arthritis, but GLP-1 receptor agonists offer benefits beyond weight reduction.
www.rheumatologyadvisor.com
November 9, 2026 at 3:30 PM
#ACR26 abstracts from @nasingh.bsky.social

⭐ Abs 2424
📊 VA cohort: RA + GU cancers (bladder, prostate, kidney), 2002-2022
🔎 DMARD use and mortality?
👉️ cs/bDMARD use not a/w 5 yr mortality for any of the cancer types
November 7, 2026 at 3:03 PM
Exercise summary

#ACR26 #GlobalSummit
November 6, 2026 at 2:22 PM
🦪If knee not involved consider other diagnoses

🦪10% will have post antibiotic arthritis (after 2 abx courses). Move into DMARD tx.

🦪MTX 15-20mg/wk, can take months. HCQ for milder cases. SSZ is third option but less used in the US.

#ACR26 #GlobalSummit
November 6, 2026 at 5:15 PM
Exercise as a DMARD - examples of exercise effects in myositis with improvement in aerobic capacity, endurance

#ACR26 #GlobalSummit
November 6, 2026 at 2:21 PM
Synovial fluid was clearly inflammatory. This was after doxy and then ceftriaxone treatment for Lyme arthritis.

Finally treated with sulfasalazine.

#ACR26 #GlobalSummit
November 6, 2026 at 5:08 PM
Gradual dose reduction of biologic & targeted #DMARDs is noninferior to continued standard-dose treatment for maintaining low disease activity in rheumatoid #arthritis patients.

@acr-journals.bsky.social

https://www.rheumatologyadvisor.com/news/dmard-tapering-rheumatoid-arthritis-disease-control/
Biologic, Targeted Synthetic DMARD Tapering Maintains Disease Control in RA
Reducing doses of biologic and targeted synthetic DMARDs effectively maintains low disease activity in patients with rheumatoid arthritis.
www.rheumatologyadvisor.com
November 3, 2026 at 9:21 PM
I get my jabs yearly. Apparently I technically qualify to get my Covid jabs every 6 months due to two factors: asplenia and being on a biologic/DMARD.

As for the illness, that is definitely your choice to mask. Do what's best for you. I wouldn't shame you if you had major health anxiety either tbh.
November 2, 2026 at 2:03 AM
I put it in my cart to remember. But my feet have a topical DMARD I use lol
October 24, 2026 at 4:59 AM
Do you take Prednisone or any other DMard for autoimmune disease? Here is a tool to predict your risk of cardiovascular disease in 10 years time
External validation study provides further evidence on clinical utility of the Expanded Risk Score for RA (ERS-RA) for predicting 10-year risk of cardiovascular disease in patients with rheumatoid arthritis

Arthritis Care & Research
doi.org/10.1002/acr....
October 16, 2026 at 6:51 AM
Rheumatology – State of the Nation summary report 2026

National Early Inflammatory Arthritis Audit (NEIAA) - 8 OCT 2026 Based on year 8 data in England and Wales, plus Jersey in 2025, this report highlights that earlier assessment and treatment continue to be associated with better patient…
Rheumatology – State of the Nation summary report 2026
National Early Inflammatory Arthritis Audit (NEIAA) - 8 OCT 2026 Based on year 8 data in England and Wales, plus Jersey in 2025, this report highlights that earlier assessment and treatment continue to be associated with better patient outcomes. Patients who start disease-modifying antirheumatic drug (DMARD) treatment at their first rheumatology appointment are significantly more likely to achieve early clinical remission, while patients presenting with higher disease activity are substantially less likely to respond to treatment. Rheumatology – State of the Nation summary report 2026
trfthealthweeklydigest.wordpress.com
October 13, 2026 at 7:07 AM
"....According to Cappelli, the findings indicated that clinicians should avoid counseling patients with autoimmune diseases to temporarily discontinue DMARD therapy for supplemental COVID vaccinations..."

www.google.com/search?q=Acc...
Google Search
www.google.com
October 9, 2026 at 11:30 PM
Reposting from The National Rheumatoid Arthritis Society (NRAS) #Rheumatoid
The importance of catching the early signs of JIA.
Join Stuart The News Guy as he reiterates a report from Specialist Pediatric Rheumatologists about recognising the signs and symptoms of JIA
youtu.be/eIttcLUsyGg?...
A New DMARD Study for RA? | NRAS News
YouTube video by NRAS_UK
youtu.be
October 8, 2026 at 3:25 PM
J&J announced topline results of Phase 4 STAR study where guselkumab (Tremfya) improved in axial Sxs & MRI outcomes in 411 biologic-naïve axial PsA pts, STAR is a 24 wk DBPCT of GUS (IL-23 inhib) in DMARD unresponsive pts. Endpoint was BASDAI @ wk24. buff.ly/tK6Q57c
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
SPRING HOUSE, Pa., Sept. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that TREMFYA® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement…
buff.ly
September 28, 2026 at 4:01 PM
Thanks! The search for a DMARD to complement my biologic for PsA continues! I'm hoping to at least be able to take my OA med again, but if the only choice for the complement clears through the liver, I think she won't okay that 😭
September 23, 2026 at 11:11 PM
JMIR Res Protocols: Remote Monitoring for Rheumatoid Arthritis Flare During Drug Tapering: #Protocol for a Prospective Observational Cohort #Study
Remote Monitoring for Rheumatoid Arthritis Flare During Drug Tapering: #Protocol for a Prospective Observational Cohort #Study
Background: Rheumatoid arthritis (RA) disease activity during disease-modifying antirheumatic drug (DMARD) tapering is commonly monitored using in-person clinical assessment and the 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP). Although effective, this approach is resource intensive and may be inconvenient for patients. Remote monitoring with patient-reported outcomes and ##Wearable sensors may enable earlier flare detection and support safer, more personalized tapering pathways. Prior pilot work suggests that accelerometry-derived physical activity, mobility, and sleep metrics correlate with RA disease activity and are acceptable to patients. Objective: This #Protocol aims to evaluate the feasibility and diagnostic accuracy of remote monitoring for detecting RA flare during DMARD tapering. The #Study will (1) continuously measure physical activity and quality metrics using wrist-worn accelerometers, (2) collect weekly Rheumatoid Arthritis Flare Questionnaire (RA-FQ) scores, (3) develop and evaluate dynamic risk prediction models using longitudinal accelerometry-derived measurements to estimate the risk of clinically confirmed flare, (4) retrospectively assess prediction accuracy against patient-reported flare, and (5) develop and evaluate a combined dynamic prediction model incorporating longitudinal accelerometry-derived measurements and total RA-FQ scores to assess whether the addition of the RA-FQ improves the prediction of clinically confirmed flare. Methods: This prospective, single-center observational cohort #Study is embedded within the Rheumatoid Arthritis DMARD Tapering (ROADMAP) clinic at Freeman Hospital, Newcastle upon Tyne, United Kingdom. Adults with clinician-confirmed RA in remission who are undergoing or are about to begin DMARD tapering will be recruited, with a target sample of 100 participants. Participants will be followed for 12 months, with clinical assessments aligned with routine ROADMAP visits at baseline and approximately months 3, 6, 9, and 12 together with ad hoc visits for suspected flare. Continuous wrist-worn accelerometry and weekly RA-FQ responses will be collected throughout follow-up. Clinical assessments will include tender and swollen joint counts, patient and physician visual analog scales, C-reactive protein, the DAS28-CRP, and Health Assessment Questionnaire Disability Index scores. The primary outcome is time to first clinically confirmed flare, defined as DAS28-CRP≥2.4 and/or at least 1 swollen joint attributable to inflammatory RA activity. Dynamic risk prediction methods, such as landmarking models, will use longitudinal accelerometry-derived physical activity, mobility, gait, and sleep measures to estimate flare risk over prespecified prediction horizons. Model performance will be assessed using time-dependent discrimination, calibration, predictive values, and lead time before clinically confirmed flare. Results: The first participant was recruited in October 2025. As of July 2026, 16 participants had been recruited. This #Protocol reports the #Study design and planned analyses; outcome analyses will be conducted after recruitment and 12-month follow-up are complete. Conclusions: This #Study will provide pilot evidence on the feasibility and accuracy of multimodal remote monitoring for RA flare detection during DMARD tapering in routine care. Findings will inform model refinement, external validation, and future larger multicenter studies evaluating clinical utility and service impact. International Registered Report Identifier (IRRID): DERR1-10.2196/99594
dlvr.it
September 21, 2026 at 8:49 PM
like if multiple antihistamines(2-4 oral, 1 nasal, topical), steroidal drugs(nasal, inhaler, topical, and oral right now), and a DMARD are barely scratching it am I just cooked?
September 18, 2026 at 4:19 PM
It’s a DMARD. It acts in the joint itself. She doesn’t think I neeed biologicals. I’m relieved, mentally. Biologicals are scary
September 13, 2026 at 12:41 AM
Urgh. I don't know you but spotted this & wanted to say I feel for you. Can be such a process to find the right DMARD. Sulfasalazine didn't work for me & I had skin reactions to hcq, too. Methotrexate shredded my bowels 🫢 until I went with subcut injectable. Hope they figure this out for you soon 💜
October 4, 2024 at 11:50 AM
Arthritis Market – Industry Trends and Forecast to 2030

"Arthritis Market - Size, Share, Demand, Industry Trends and Opportunities Global Arthritis Market ,By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Treatment (Synovectomy, Tendon…
Arthritis Market – Industry Trends and Forecast to 2030
"Arthritis Market - Size, Share, Demand, Industry Trends and Opportunities Global Arthritis Market ,By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Treatment (Synovectomy, Tendon Repair, Joint Fusion, Symptomatic Treatment, Intermediate Corticosteroid Therapies, DMARD Therapies), Rheumatoid Diagnosis (C.R.P. Test, C.C.P., E.S.R. Test), Osteoarthritis Type (Hip, Spinal, Knee, Foot and Ankle, Shoulder, Hand), Osteoarthritis Treatment (Medication, Drugs, Assistive Devices, Surgery, Therapy), Osteoarthritis Diagnosis (Imaging, Joint Fluid Analysis, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Clinics, Household, Medical Institutes, Research Organizations, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Drug Stores) – Industry Trends.
databridgemarketresearch2.wordpress.com
May 19, 2025 at 12:01 PM
Arthritis Market  Industry Trends and Forecast to 2030

"Arthritis Market - Size, Share, Demand, Industry Trends and Opportunities Global Arthritis Market ,By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Treatment (Synovectomy, Tendon…
Arthritis Market  Industry Trends and Forecast to 2030
"Arthritis Market - Size, Share, Demand, Industry Trends and Opportunities Global Arthritis Market ,By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Treatment (Synovectomy, Tendon Repair, Joint Fusion, Symptomatic Treatment, Intermediate Corticosteroid Therapies, DMARD Therapies), Rheumatoid Diagnosis (C.R.P. Test, C.C.P., E.S.R. Test), Osteoarthritis Type (Hip, Spinal, Knee, Foot and Ankle, Shoulder, Hand), Osteoarthritis Treatment (Medication, Drugs, Assistive Devices, Surgery, Therapy), Osteoarthritis Diagnosis (Imaging, Joint Fluid Analysis, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Clinics, Household, Medical Institutes, Research Organizations, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Drug Stores) – Industry Trends.
databridgemarketresearch2.wordpress.com
May 13, 2025 at 8:38 AM
Arthritis Market – Industry Trends and Forecast to 2030

"Arthritis Market - Size, Share, Demand, Industry Trends and Opportunities Global Arthritis Market ,By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Treatment (Synovectomy, Tendon…
Arthritis Market – Industry Trends and Forecast to 2030
"Arthritis Market - Size, Share, Demand, Industry Trends and Opportunities Global Arthritis Market ,By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Treatment (Synovectomy, Tendon Repair, Joint Fusion, Symptomatic Treatment, Intermediate Corticosteroid Therapies, DMARD Therapies), Rheumatoid Diagnosis (C.R.P. Test, C.C.P., E.S.R. Test), Osteoarthritis Type (Hip, Spinal, Knee, Foot and Ankle, Shoulder, Hand), Osteoarthritis Treatment (Medication, Drugs, Assistive Devices, Surgery, Therapy), Osteoarthritis Diagnosis (Imaging, Joint Fluid Analysis, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Clinics, Household, Medical Institutes, Research Organizations, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Drug Stores) – Industry Trends.
databridgemarketresearch2.wordpress.com
May 8, 2025 at 12:44 PM